964 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 3
Zhu et al.
(12) (a) Bayer, A. J.; Bullock, R.; Jones, R. W.; Wilkinson, D.; Paterson,
K. R.; Jenkins, L. Evaluation of the safety and immunogenicity of
synthetic Aβ42 (AN1792) in patients with AD. Neurology 2005, 64,
94–101. (b) Gilman, S.; Koller, M.; Black, R. S.; Jenkins, L.; Griffith,
S. G.; Fox, N. C. Clinical effects of Aβ immunization (AN1792) in
patients with AD in an interrupted trial. Neurology 2005, 64, 1553–
1562. (c) Hock, C.; Konietzko, U.; Streffer, J. R.; Tracy, J.; Signorell,
A.; M€uller-Tilmanns, B. Antibodies against b-amyloid slow cognitive
decline in Alzheimer's disease. Neuron 2003, 38, 547–554. (d) Fox,
N. C.; Black, R. S.; Gilman, S.; Rossor, M. N.; Griffith, S. G.; Jenkins,
L. Effects of Ab immunization (AN1792) on MRI measures of cerebral
volume in Alzheimer disease. Neurology 2005, 64, 1563–1572.
(e) DaSilva, K. A; Aubert, I.; McLaurin, J. Vaccine Development for
Alzheimer's Disease. Curr. Pharm. Des. 2006, 12, 4283–4293.
(13) (a) Hussain, I.; Powell, D.; Howlett, D. R.; Tew, D. G.; Meek,
T. D.; Chapman, C.; Gloger, I. S.; Murphy, K. E.; Southan, C. D.;
Ryan, D. M; Smith, T. S.; Simmons, D. L.; Walsh, F. S.; Dingwall,
C.; Christie, G. Identification of a novel aspartic protease (Asp 2)
as beta-secretase. Mol. Cell Neurosci. 1999, 14, 419–427. (b) Sinha,
S.; Anderson, J. P.; Barbour, R.; Basi, G. S.; Caccavello, R.; Davis, D.;
Doan, M.; Dovey, H. F.; Frigon, N.; Hong, J.; Jacobson-Croak, K.;
Jewett, N.; Keim, P.; Knops, J.; Lieberburg, I.; Power, M.; Tan, H.;
Tatsuno, G.; Tung, J.; Schenk, D. Purification and cloning of amyloid
precursor protein betasecretase from human brain. Nature 1999, 402,
537–540. (c) Vassar, R.; Bennett, B. D.; Babu-Khan, S.; Kahn, S.;
Mendiaz, E. A.; Denis, P.; Teplow, D. B.; Ross, S.; Amarante, P.;
Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S; Lile, J.;
Jarosinski, M. A.; Biere, A. L.; Curran, E.; Burgess, T.; Louis, J. C.
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by
the transmembrane aspartic protease BACE. Science 1999, 286, 735–
741. (d) Yan, R.; Bienkowski, M. J.; Shuck, M. E.; Miao, H.; Tory,
M. C.; Pauley, A. M.; Brashier, J. R.; Stratman, N. C.; Mathews, W. R.;
Buhl, A. E.; Carter, D. B.; Tomasselli, A. G.; Parodi, L. A.; Heinrikson,
R. L.; Gurney, M. E Membrane-anchored aspartyl protease with
Alzheimer's disease beta-secretase activity. Nature 1999, 402, 533–
537.
(14) (a) Luo, Y.; Bolon, B.; Kahn, S.; Bennett, B. D.; Babu-Khan, S.;
Denis, P.; Fan, W.; Kha, H; Zhang, J.; Gong, Y.; Martin, L.; Louis,
J. C.; Yan, Q.; Richards, W. G.; Citron, M; Vassar, R Mice
deficient in BACE1, the Alzheimer’s betasecretase, have normal
phenotype and abolished beta-amyloid generation. Nat. Neurosci.
2001, 4, 231–232. (b) Luo, Y.; Bolon, B.; Damore, M. A.; Fitzpatrick,
D.; Liu, H.; Zhang, J.; Yan, Q.; Vassar, R.; Citron, M. BACE1 (beta-
secretase) knockout mice do not acquire compensatory gene expression
changes or develop neural lesions over time. Neurobiol. Dis. 2003, 14,
81–88.
(15) (a) Willem, M.; Garratt, A. N.; Novak, B.; Citron, M.; Kaufmann,
S.; Rittger, A.; DeStrooper, B.; Saftig, P.; Birchmeier, C.; Haass, C.
Control of Peripheral Nerve Myelination by the b-Secretase
BACE1. Science 2006, 314, 664–666. (b) Wang, H.; Song, L.; Laird,
F.; Wong, P. C.; Lee, H.-K. BACE1 Knock-Outs Display Deficits in
Activity-Dependent Potentiation of Synaptic Transmission at Mossy
Fiber to CA3 Synapses in the Hippocampus. J. Neurosci. 2008, 28,
8677–8681.
(16) Ohno, M.; Sametsky, E. A.; Younkin, L. H.; Oakley, H.; Younkin,
S. G.; Citron, M.; Vassar, R.; Disterhoft, J. F. BACE1 deficiency
rescues memory deficits and cholinergic dysfunction in a mouse
model of Alzheimer’s disease. Neuron 2004, 41, 27–33.
(17) (a) Farzan, M.; Schnitzler, C. E.; Vasilieva, N.; Leung, D.; Choe,
H. BACE2, a beta-secretase homolog, cleaves at the beta site and
within the amyloid-beta region of the amyloid-beta precur-
sor protein. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 9712–9717.
(b) Saunders, A. J.; Kim, T.-M.; Tanzi, R. E. BACE Maps to Chro-
mosome 11 and a BACE Homolog, BACE2, Reside in the Obligate
Down Syndrome Region of Chromosome 21. Science 1999, 286,
1255a.
(18) (a) Sidera, C.; Liu, C.; Austen, B. Pro-domain removal in ASP-2
and the cleavage precursor are influenced by pH. BMC Biochem.
was later confirmed: Stachel, S. J; Coburn, C. A.; Rush, D.; Jones,
K. L. G.; Zhu, H.; Rajapakse, H.; Graham, S. L.; Simon, A.; Holloway,
M. K.; Allison, T. J.; Munshi, S. K.; Espeseth, A. S.; Zuck, P.; Colussi,
D.; Wolfe, A.; Pietrak, B. L.; Lai, M.-T.; Vacca, J. P. Discovery of
aminoheterocycles as a novel b-secretase inhibitor class: pH depen-
dence on binding activity part 1. Bioorg. Med. Chem. Lett. 2009, 19,
2977–2980. However, in our hands, the BACE1 cellular IC50 and
enzyme Ki can be in good agreement at the in vitro assay pH (5)
depending on the inhibitor structures and other factors such as pgp
efflux activities.
of efficacious BACE inhibitors. Curr. Opin. Drug Discovery Dev.
2006, 9, 776–791.
(20) Ghosh, A. K.; Shin, D.; Downs, D.; Koelsch, G.; Lin, X.;
Ermolieff, J.; Tang, J. Design of Potent Inhibitors for Human
Brain memapsin 2 ( β-Secretase). J. Am. Chem. Soc. 2000, 122,
3522–3523.
(21) (a) Maillard, M.; Hom, C.; Gailunas, A.; Jagodzinska, B.; Fang,
L. Y.; Vargese, J.; Freskos, J. N.; Pulley, S. R.; Beck, J. P.;
Tenbrink, R. E. Compounds to treat Alzheimer’s disease. Patent
WO2002002512, 2002; (b) Maillard, M. C.; Hom, R. K.; Benson, T. E.;
Moon, J. B.; Mamo, S.; Bienkowski, M.; Tomasselli, A. G.; Woods,
D. D.; Prince, D. B.; Paddock, D. J.; Emmons, T. L.; Tucker, J. A.;
Dappen, M. S.; Brogley, L.; Thorsett, E. D.; Jewett, N.; Sinha, S.;
Varghese, J. Design, Synthesis, and Crystal Structure of Hydroxyethyl
Secondary Amine-Based Peptidomimetic Inhibitors of Human .beta.-
Secretase. J. Med. Chem. 2007, 50, 776–781.
(22) (a) Hyland, L. J.; Tmaszek, T. A., Jr.; Meek, T. D. Human
immunodeficiency virus-1 protease. 2. Use of pH rate studies and
solvent kinetic isotope effects to elucidate details of chemical
mechanism. Biochemistry 1991, 30, 8454–8463. (b) For a general
review on this topic: Bursavich, M. G.; Rich, D. H. J. Med. Chem.
2002, 45, 541–558. (c) Toulokhonova, L.; Metzler, W. J.; Witmer,
M. R.; Copeland, R. A.; Marcinkeviciene, J. Kinetic Studies on beta-
Site Amyloid Precursor Protein-Cleaving Enzyme (BACE). J. Biol.
Chem. 2003, 278, 4582–4589.
(23) Silvestri, R. Boom in the development of non-peptidic beta-secre-
tase (BACE1) inhibitors for the treatment of Alzheimer’s disease.
Med. Res. Rev., 2009, 29, 295-338 and references therein.
(24) Wang, Y.-S.; Strickland, C.; Voigt, J. H.; Kennedy, M. E.; Beyer,
B. M.; Senior, M. M.; Smith, E. M.; Nechuta, T. L.; Madison,
V. S.; Czarniecki, M.; McKittrick, B. A.; Stamford, A. W.; Parker,
E. M.; Hunter, J. C.; Greenlee, W. J.; Wyss, D. F.; Application of
Fragment-Based NMR Screening, X-ray Crystallography, Struc-
ture-Based Design, and Focused Chemical Library Design to
Identify Novel μM Leads for the Development of nM BACE-1
( β-site APP Cleaving Enzyme 1) Inhibitors.J. Med. Chem. 2010, 53,
DOI: 10.1021/jm901472u.
(25) Albert, A.; Goldacre, R.; Phillips, J. The Strength of Heterocyclic
Bases. J. Chem. Soc. 1948, 2240–2249.
(26) See ref 23b for more detailed discuss about the flap and its conforma-
tions.
(27) (a) Detailed description of the protonation states will be a subject
of another publication. (b) It was suggested that the most stable
protonation state for the apo-protein is the dideprotonated state
Rajamani, R.; Reynolds, C. H. Modeling the Protonation States of
the Catalytic Aspartates in beta-Secretase. J. Med. Chem. 2004, 47,
5159–5166.
(28) (a) Hueper, W. C.; Ichniowsky, C. T. Toxicopathologic studies on
S-methylisothiourea. Virchows Arch. Pathol. Anat. und Physiol.
Klin. Med. 1944, 37, 253–263. (b) Dieke, S. H.; Allen, G. S.; Richter,
C. P. The acute toxicity of thioureas and related compounds to wild and
domestic Norway rats. J. Pharmacol. 1947, 90, 260–270.
(29) Peterlin-Masic, L.; Cesar, J.; Zega, A. Metabolism-Directed Opti-
misation of Antithrombotics: The Prodrug Principle. Curr. Pharm.
Des. 2006, 12, 73–91.
(30) (a) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.
Experimental and computational approaches to estimate solubility
and permeability in drug discovery and development settings. Adv.
Drug Delivery Rev. 2001, 46, 3–26. (b) Veber, D. F. et al. Molecular
properties that influence the oral bioavailability of drug candidates.
J. Med. Chem. 2002, 45, 2615-2623. (c) Lipinski, C. A. Lead- and
drug-like compounds: the rule-of-five revolution. Drug Discovery
Today: Technol. 2004, 1, 337–341.
(31) See ref 26.
(32) (a) Grazybowski, A. K.; Datta, S. P. The ionization constant of the
protonated form of creatinine. J. Chem. Soc. 1964, 187–196. (b)
Winiwarter, S.; Bonham, N. M.; Ax, F.; Hallberg, A.; Lenneras, H.;
Karlen, A. Correlation of human jejunal permeability (in vivo) of
drugs with experimentally and theoretically derived parameters. A
multivariate data analysis approach. J. Med. Chem. 1998, 41, 4939–
4949.
(33) Lindel, T.; Hoffmann, H. Synthesis of dispacamide from the
marine sponge Agelas dispar. Tetrahedron Lett. 1997, 38, 8935–
8938.
(34) For an example: Ishizumi, K.; Ohashi, N.; Tanno, N. Stereospecific
total synthesis of 9-aminoanthracyclines: (þ)-9-amino-9-deoxy-
daunomycin and related compounds. J. Org. Chem. 1987, 52,
4477–4485.
(35) Altmann, E.; Nebel, K.; Mutter, M. Versatile stereoselective
synthesis of completely protected trifunctional alpha-methylated
alpha-amino acid starting from alanine. Helv. Chim. Acta 1991, 74,
800–806.
(19) (a) Stachel, S. J. Progress toward the development of a viable
BACE-1 inhibitor. Drug Dev. Res. 2009, 70, 101–110. (b) Durham,
T. B.; Shepherd, T. A. Progress toward the discovery and development